Blood Plasma Derivatives Market – Overview
The upsurge in the occurrence of blood related diseases is driving the growth of the market at an accelerated pace. Market focused reports related to the healthcare sector among others recently have been made available by Market Research Future which publishes reports on this market. The market is estimated to earn USD 40,475.8 Million in 2030 while expanding with a CAGR of approximately 10.50 percent during the forecast period.
Increasing range of clinical applications has favorably driven the growth of the blood plasma derivatives market in the past few years. The demand for blood plasma derivatives has increased the preservation techniques and technologies that are available, which have added to the expansion of the market. Hepatitis B, HIV, and Hepatitis C are among some of the diseases which are leading to an increase in the demand forecasted for the blood plasma derivatives. Rising inflow of investments into research and development for the market will create numerous opportunities for its growth.
Request Free Sample Copy at:
The blood plasma derivatives market has been segmented into types, application and end users. The segmentation on the basis of type comprises of anti-thrombin, albumin, fresh frozen plasma (FFP), intravenous immunoglobulin (IVIG) and others. The others segment type includes Factor IX, Factor VII, and Alpha 1 proteinase inhibitor concentrate. The application basis of the market is segmented into Hemophilia B, Hemophilia A, HIV, Hepatitis C, Hepatitis B, Thrombocytosis, and others. The other application comprises of Von Willebrand disease. Lastly, the end users segment comprises of diagnostic centers, hospitals, clinics, blood transfusion centers and others.
Detailed Regional Analysis
The blood plasma derivatives market globally comprises regions such as Asia-Pacific, Europe, North America, Middle East and Africa. The North American region is the major region for the market. The North American market for blood plasma derivatives is projected to grow at a CAGR of 4.25 percent which is likely to achieve US$ 35.50 billion in revenues as compared to US$ 20 billion in the year 2016 by the end of the forecast period. Awareness around the use of plasma derivatives for patients suffering from infectious diseases is fuelling the market growth in the North American region. The European region is the second major market for blood plasma derivatives and is estimated to grow at a CAGR of 3.8 percent. Widespread research on safe blood transfusion procedures by healthcare organizations and research laboratories will favor the progress of this market in the European region. Whereas, the Asia Pacific region is estimated to be the most rapidly growing market for the market. India is estimated to be the fastest developing market in the region. The demand for plasma derivatives for inactivation of HIV will completely benefit the demand of plasma derivatives in the Asia Pacific region. The market for blood plasma derivatives is demonstrating stable growth in the Middle East and African region.
Global Competitive Analysis
The market competitors are devising their blueprints for corporate strategy in such a manner that can bring about the best outcomes for growth in the current scenario, while also enhancing their product’s significance. The companies in this market are getting accustomed to the state of events by maintaining financial liquidity and effecting portfolio upgrades. The prospects for growth in the market appear to be promising through the forecast period. The constant supply of customer value has heightened the market worth. The competency to fuel competitive proficiencies is one of the leading causes powering their efforts in this period. The rising levels of diversification in the industry, have allowed the businesses to apply many prospects available in the market. Additionally, the challengers are handling the competitive environment by driving the market progress factors to their gain.
The major competitors in this market are SK Plasma (Korea), Fusion Healthcare (India), Grifols (Germany), CSL Limited (Australia), Baxter International Inc. (U.S). Other contenders in this market are Biotest AG (Germany), Octapharma AG (Germany) and Bain Capital (U.S).
Jun 2017 CSL has moved into China’s market after a long awaited move which will in the future allow CSL to offer a full range of plasma-related therapies in China which is among the world's rapidly growing healthcare market.
CSL had agreed to pay $US352 million for 80 per cent of Wuhan Zhong Yuan Rui De Biologics which a profitable business with sales of just $US30 million based in central China. CSL has been importing albumin which is a blood plasma derivative used to stem bleeding in trauma victims into China for two decades but has been banned from importing additional plasma derivatives such as immunoglobulins.
Browse Detailed TOC with COVID-19 Impact Analysis at:
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: [email protected]